Ondine Biomedical, Inc. (GB:OBI) has released an update.
Ondine Biomedical Inc. reported significant growth in 2023, with revenues doubling to $1.2 million and new hospital deployments increasing by 167%. The company is preparing for Phase 3 clinical trials in the U.S. for its Steriwave antimicrobial technology, which has been adopted by the NHS in the UK and shows promise in reducing hospital infections and associated costs. Ondine’s successful year also saw the appointment of Dr. Simon Sinclair as Chief Medical Officer to lead upcoming clinical trials.
For further insights into GB:OBI stock, check out TipRanks’ Stock Analysis page.
